凯莱英(002821)：各项业务持续向好 25Q1公司业绩及时回暖

Core Insights - The company reported a revenue of 1.541 billion yuan for Q1 2025, representing a year-on-year growth of 10.10% [1][2] - The net profit attributable to shareholders reached 327 million yuan, with a year-on-year increase of 15.83% [1][3] - The growth in net profit outpaced revenue growth by 5.73 percentage points, indicating improved efficiency [4] Revenue Performance - The revenue from the small molecule business remained stable compared to the same period last year, while the emerging business saw a significant growth of over 80% year-on-year [2] - The company is focusing on expanding its CDMO services in the small molecule sector, with an expectation of 12 projects in the validation batch stage for 2025 [5] Profitability Analysis - The net profit growth of 15.83% is attributed to the rapid development of emerging businesses and ongoing cost reduction and efficiency improvement efforts [4][5] - The company is optimistic about the continuous improvement of its performance in 2025, supported by a robust order reserve in the small molecule business and successful project validations in the peptide sector [5] Investment Outlook - The projected net profits for 2025 to 2027 are 1.133 billion yuan, 1.321 billion yuan, and 1.521 billion yuan, with year-on-year growth rates of 19.4%, 16.6%, and 15.1% respectively [6] - The expected EPS for 2025 is 3.14 yuan per share, with a target price of 94.20 yuan per share based on a PE ratio of 30 times, indicating a "Buy-A" investment rating [6]